{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360002218153423616.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/dom.12540"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fdom.12540"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12540"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/dom.12540"}},{"identifier":{"@type":"URI","@value":"https://dom-pubs.pericles-prod.literatumonline.com/doi/pdf/10.1111/dom.12540"}},{"identifier":{"@type":"PMID","@value":"26179754"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in\n                    <scp>J</scp>\n                    apanese patients with type 2 diabetes: a randomized, open‐label, phase\n                    <scp>III</scp>\n                    , non‐inferiority study"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n                    <jats:title>Aims</jats:title>\n                    <jats:p>\n                      To evaluate 0.75 mg of dulaglutide, a once‐weekly glucagon‐like peptide‐1 receptor agonist, compared with once‐daily insulin glargine for glycaemic control in\n                      <jats:styled-content style=\"fixed-case\">J</jats:styled-content>\n                      apanese patients with type 2 diabetes (\n                      <jats:styled-content style=\"fixed-case\">T2D</jats:styled-content>\n                      ).\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>\n                      In this phase\n                      <jats:styled-content style=\"fixed-case\">III</jats:styled-content>\n                      , randomized, open‐label, parallel‐group, 26‐week study, 361 patients with inadequately controlled\n                      <jats:styled-content style=\"fixed-case\">T2D</jats:styled-content>\n                      receiving sulphonylureas and/or biguanides, aged ≥20 years, with glycated haemoglobin (\n                      <jats:styled-content style=\"fixed-case\">HbA1c</jats:styled-content>\n                      ) levels 7.0–10.0% (53–86 mmol/mol), inclusive, were randomized (1 : 1) to receive dulaglutide or glargine. Participants and investigators were not masked to treatment allocation. The primary measure was change from baseline in\n                      <jats:styled-content style=\"fixed-case\">HbA1c</jats:styled-content>\n                      at 26 weeks, analysed using a mixed‐effects model for repeated measures, with a predefined non‐inferiority margin of 0.4%.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>\n                      At week 26, least‐squares (\n                      <jats:styled-content style=\"fixed-case\">LS</jats:styled-content>\n                      ) mean (standard error) reductions in\n                      <jats:styled-content style=\"fixed-case\">HbA1c</jats:styled-content>\n                      were −1.44 (0.05)% [−15.74 (0.55) mmol/mol] in the dulaglutide group and −0.90 (0.05)% [−9.84 (0.55) mmol/mol] in the glargine group. The mean between‐group treatment difference in\n                      <jats:styled-content style=\"fixed-case\">HbA1c</jats:styled-content>\n                      was −0.54% (95%\n                      <jats:styled-content style=\"fixed-case\">CI</jats:styled-content>\n                      −0.67, −0.41) [−5.90 mmol/mol (95%\n                      <jats:styled-content style=\"fixed-case\">CI</jats:styled-content>\n                      −7.32, −4.48)]; p < 0.001. Dulaglutide significantly reduced body weight compared with glargine at week 26 (\n                      <jats:styled-content style=\"fixed-case\">LS</jats:styled-content>\n                      mean difference −1.42 kg, 95%\n                      <jats:styled-content style=\"fixed-case\">CI</jats:styled-content>\n                      −1.89, −0.94; p < 0.001). The most frequent adverse events with dulaglutide treatment were nasopharyngitis and gastrointestinal symptoms. The incidence of hypoglycaemia was significantly lower with dulaglutide [47/181 (26%)] compared with glargine [86/180 (48%)], p < 0.001.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion</jats:title>\n                    <jats:p>\n                      In\n                      <jats:styled-content style=\"fixed-case\">J</jats:styled-content>\n                      apanese patients with\n                      <jats:styled-content style=\"fixed-case\">T2D</jats:styled-content>\n                      uncontrolled on sulphonylureas and/or biguanides, once‐weekly dulaglutide was superior to once‐daily glargine for reduction in\n                      <jats:styled-content style=\"fixed-case\">HbA1c</jats:styled-content>\n                      at 26 weeks. Although dulaglutide increased gastrointestinal symptoms, it was well tolerated, with an acceptable safety profile.\n                    </jats:p>\n                  </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380568466103168768","@type":"Researcher","foaf:name":[{"@value":"E. Araki"}],"jpcoar:affiliationName":[{"@value":"Department of Metabolic Medicine Faculty of Life Sciences, Kumamoto University  Kumamoto Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380847871306604673","@type":"Researcher","foaf:name":[{"@value":"N. Inagaki"}],"jpcoar:affiliationName":[{"@value":"Department of Diabetes, Endocrinology and Nutrition Kyoto University Graduate School of Medicine  Kyoto Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380847871306604544","@type":"Researcher","foaf:name":[{"@value":"Y. Tanizawa"}],"jpcoar:affiliationName":[{"@value":"Division of Endocrinology, Metabolism, Hematological Science and Therapeutics Yamaguchi University Graduate School of Medicine  Yamaguchi Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380847871306604674","@type":"Researcher","foaf:name":[{"@value":"T. Oura"}],"jpcoar:affiliationName":[{"@value":"Eli Lilly Japan K.K.  Kobe Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380847871306604546","@type":"Researcher","foaf:name":[{"@value":"M. Takeuchi"}],"jpcoar:affiliationName":[{"@value":"Eli Lilly Japan K.K.  Kobe Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380847871306604672","@type":"Researcher","foaf:name":[{"@value":"T. Imaoka"}],"jpcoar:affiliationName":[{"@value":"Eli Lilly Japan K.K.  Kobe Japan"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"14628902"},{"@type":"EISSN","@value":"14631326"}],"prism:publicationName":[{"@value":"Diabetes, Obesity and Metabolism"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2015-08-20","prism:volume":"17","prism:number":"10","prism:startingPage":"994","prism:endingPage":"1002"},"reviewed":"false","dc:rights":["http://creativecommons.org/licenses/by-nc/4.0/"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fdom.12540"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12540"},{"@id":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/dom.12540"},{"@id":"https://dom-pubs.pericles-prod.literatumonline.com/doi/pdf/10.1111/dom.12540"}],"createdAt":"2015-07-14","modifiedAt":"2025-10-31","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Blood%20Glucose","dc:title":"Blood Glucose"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Gastrointestinal%20Diseases","dc:title":"Gastrointestinal Diseases"},{"@id":"https://cir.nii.ac.jp/all?q=Recombinant%20Fusion%20Proteins","dc:title":"Recombinant Fusion Proteins"},{"@id":"https://cir.nii.ac.jp/all?q=Biguanides","dc:title":"Biguanides"},{"@id":"https://cir.nii.ac.jp/all?q=Glucagon-Like%20Peptides","dc:title":"Glucagon-Like Peptides"},{"@id":"https://cir.nii.ac.jp/all?q=Insulin%20Glargine","dc:title":"Insulin Glargine"},{"@id":"https://cir.nii.ac.jp/all?q=Drug%20Administration%20Schedule","dc:title":"Drug Administration Schedule"},{"@id":"https://cir.nii.ac.jp/all?q=Japan","dc:title":"Japan"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Hypoglycemic%20Agents","dc:title":"Hypoglycemic Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Glycated%20Hemoglobin","dc:title":"Glycated Hemoglobin"},{"@id":"https://cir.nii.ac.jp/all?q=Body%20Weight","dc:title":"Body Weight"},{"@id":"https://cir.nii.ac.jp/all?q=Original%20Articles","dc:title":"Original Articles"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Hypoglycemia","dc:title":"Hypoglycemia"},{"@id":"https://cir.nii.ac.jp/all?q=Immunoglobulin%20Fc%20Fragments","dc:title":"Immunoglobulin Fc Fragments"},{"@id":"https://cir.nii.ac.jp/all?q=Sulfonylurea%20Compounds","dc:title":"Sulfonylurea Compounds"},{"@id":"https://cir.nii.ac.jp/all?q=Diabetes%20Mellitus,%20Type%202","dc:title":"Diabetes Mellitus, Type 2"},{"@id":"https://cir.nii.ac.jp/all?q=Nasopharyngitis","dc:title":"Nasopharyngitis"},{"@id":"https://cir.nii.ac.jp/all?q=Drug%20Therapy,%20Combination","dc:title":"Drug Therapy, Combination"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040000782245886208","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"25293210"},{"@type":"JGN","@value":"JP25293210"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-25293210/"}],"notation":[{"@language":"ja","@value":"単離小腸K細胞を用いたGIP合成・分泌機構の解明"},{"@language":"en","@value":"The mechanisms of GIP secretion from enteroendocrine K cells"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004232064416000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145494873600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lessons from glargine trials: What is the goal fasting glucose with basal insulin? (来自甘精胰岛素临床试验的经验教训：使用基础胰岛素治疗的空腹血糖目标是什么？)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146560358144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Titration of Insulin Glargine in Patients with Type 2 Diabetes Mellitus in Asia: Physician- Versus Patient-Led? Rationale of the Asian Treat to Target Lantus Study (ATLAS)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013168740301440","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710751031680","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of <scp>G</scp>et<scp>G</scp>oal‐<scp>S</scp>"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620444698112","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360568466103168896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094989514368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095115013888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660434297088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in\n                    <scp>J</scp>\n                    apanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase\n                    <scp>III</scp>\n                    study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569044572800","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570952004480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Dosing of Insulin Glargine to Achieve the Treatment Target in Japanese Type 2 Diabetes on a Basal Supported Oral Therapy Regimen in Real Life: ALOHA Study Subanalysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044753526528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045389408256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reduced Hypoglycemia Risk With Insulin Glargine"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137046517179776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994296179712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Glucagon-like peptide 1 (GLP-1) and eating"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995668397312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995750760192","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Defining and Reporting Hypoglycemia in Diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469708280448","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470440813440","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"World Medical Association Declaration of Helsinki"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945710309888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418714358784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418990353024","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419231021312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Randomized, double‐blind, placebo‐controlled trial of the once‐daily\n                    <scp>GLP</scp>\n                    ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (\n                    <scp>GetGoal</scp>\n                    ‐L‐Asia)"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419436203520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894382462720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895726188160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369045639040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845235891840","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Taspoglutide, a once‐weekly glucagon‐like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open‐label randomized trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845276291200","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319568946944","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320304397696","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793870157824","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in <scp>A</scp>sian patients with type 2 diabetes mellitus"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270151834624","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Incretin Therapies: Effects Beyond Glycemic Control"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270638674048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach"}]},{"@id":"https://cir.nii.ac.jp/crid/1370002218153423641","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetic patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1370285710480861056","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of once‐weekly dulaglutide versus insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD‐2)"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204275766144","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"週1回投与が可能な持効型GLP-1受容体作動薬デュラグルチド（遺伝子組換え）の薬理学的特性および臨床試験成績"},{"@language":"en","@value":"Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)"},{"@value":"新薬紹介総説 週1回投与が可能な持効型GLP-1受容体作動薬デュラグルチド(遺伝子組換え)の薬理学的特性および臨床試験成績"},{"@language":"ja-Kana","@value":"シンヤク ショウカイ ソウセツ シュウ 1カイ トウヨ ガ カノウ ナ ジコウガタ GLP-1 ジュヨウタイ サドウヤク デュラグルチド(イデンシ クミカエ)ノ ヤクリガクテキ トクセイ オヨビ リンショウ シケン セイセキ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206299575040","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206301011072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206301734528","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206302660736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206303197952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681278553984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681279147008","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/dom.12540"},{"@type":"KAKEN","@value":"PRODUCT-20630555"},{"@type":"OPENAIRE","@value":"doi_dedup___::6b82c01af79042ed03cf956b263b7f32"},{"@type":"CROSSREF","@value":"10.1507/endocrj.ej17-0189_references_DOI_KmGyOHfr5Hbgp0N0qod3Pna6Yt7"},{"@type":"CROSSREF","@value":"10.1507/endocrj.ej15-0518_references_DOI_KmGyOHfr5Hbgp0N0qod3Pna6Yt7"},{"@type":"CROSSREF","@value":"10.1507/endocrj.ej16-0365_references_DOI_KmGyOHfr5Hbgp0N0qod3Pna6Yt7"},{"@type":"CROSSREF","@value":"10.1111/jdi.13749_references_DOI_KmGyOHfr5Hbgp0N0qod3Pna6Yt7"},{"@type":"CROSSREF","@value":"10.1007/s12325-019-01065-7_references_DOI_KmGyOHfr5Hbgp0N0qod3Pna6Yt7"},{"@type":"CROSSREF","@value":"10.1111/dom.12602_references_DOI_KmGyOHfr5Hbgp0N0qod3Pna6Yt7"},{"@type":"CROSSREF","@value":"10.1507/endocrj.ej16-0552_references_DOI_KmGyOHfr5Hbgp0N0qod3Pna6Yt7"},{"@type":"CROSSREF","@value":"10.1507/endocrj.ej15-0401_references_DOI_KmGyOHfr5Hbgp0N0qod3Pna6Yt7"},{"@type":"CROSSREF","@value":"10.1254/fpj.146.215_references_DOI_KmGyOHfr5Hbgp0N0qod3Pna6Yt7"},{"@type":"CROSSREF","@value":"10.1507/endocrj.ej16-0428_references_DOI_KmGyOHfr5Hbgp0N0qod3Pna6Yt7"}]}